InSysBio to announce a new collaborative project with BeOne Medicines
The project aims at Quantitative Systems Pharmacology modeling of a T-cell engager to identify first-in-human dose and predict optimal step-up dosing regimen
LIMASSOL,
In this project mechanistic translational modeling will be applied to support selection of minimal recommended starting dose and step-up dosing regimen to mitigate cytokine release syndrome and optimize dose-escalation clinical study design.
"Nowadays, trimer-based mechanistic modeling has become an essential tool to guide the selection of an appropriate starting dose for first-in-human trials of T-cell engagers, ensuring the dose is high enough to be effective while avoiding sub-therapeutic levels and multiple dose escalation steps," said
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol,
Logo: https://mma.prnewswire.com/media/2801933/5728487/InSysBio_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/insysbio-to-announce-a-new-collaborative-project-with-beone-medicines-302669033.html
SOURCE InSysBio
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Infinix Unveils HOT 70 Pro 5G: More Expressive, More Interactive, More Pro
- Baidu to Pursue Voluntary Conversion to Dual-Primary Listing on The Main Board of The Stock Exchange of Hong Kong Limited
- Neusoft Selected in KPMG Chinese Rehabilitation and Elderly Care 50 List
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share